2021 ACCOMPLISHMENTS REPORT
Sylvester Investigator’s Hodgkin Lymphoma Protocol Could Change Care for Relapsed, Refractory Patients. The results of a Phase 2 study looking at treating relapsed or refractory Hodgkin lymphoma with a new drug protocol were outstanding. They even surprised one of the world’s leading lymphoma experts, Craig Moskowitz, M.D., physician in chief of the Oncology Service Line at Sylvester Comprehensive Cancer Center.
Read Full Story